Abstract
Purpose: Voriconazole (VORI) has become an important drug for treating aspergillus infections in transplant recipients. As a potent inhibitor of the 3A4 enzyme, it interacts with numerous other transplant medications, including sirolimus (SIR). Concomitant administration of VORI with SIR is currently contraindicated by the manufacturer following a manufacturer-sponsored study that reported an 11-fold increase in SIR levels during VORI administration in healthy volunteers. The purpose of this study is to determine the effect of VORI on SIR levels in transplant recipients in order to develop recommendations for SIR dose-reduction when starting concomitant VORI.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
